US 12,303,551 B2
Cellular immunotherapy compositions and uses thereof
Daniel Mark Corey, Menlo Park, CA (US)
Assigned to Cero Therapeutics Holdings, Inc., South San Francisco, CA (US)
Appl. No. 17/040,472
Filed by CERO THERPEUTICS HOLDINGS, INC., South San Francisco, CA (US)
PCT Filed Mar. 27, 2019, PCT No. PCT/US2019/024442
§ 371(c)(1), (2) Date Sep. 22, 2020,
PCT Pub. No. WO2019/191340, PCT Pub. Date Oct. 3, 2019.
Claims priority of provisional application 62/734,863, filed on Sep. 21, 2018.
Claims priority of provisional application 62/652,838, filed on Apr. 4, 2018.
Claims priority of provisional application 62/649,541, filed on Mar. 28, 2018.
Prior Publication US 2021/0023135 A1, Jan. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); A61K 35/17 (2025.01); A61K 39/00 (2006.01); A61K 40/11 (2025.01); A61K 40/24 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); A61K 40/46 (2025.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61P 37/04 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01)
CPC A61K 38/1774 (2013.01) [A61K 35/17 (2013.01); A61K 38/177 (2013.01); A61K 40/11 (2025.01); A61K 40/24 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); A61K 40/46 (2025.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 37/04 (2018.01); C07K 14/70503 (2013.01); C07K 14/7051 (2013.01); C07K 14/70578 (2013.01); C07K 14/70596 (2013.01); C07K 16/28 (2013.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/035 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01)] 26 Claims
 
1. A combination cellular immunotherapy composition comprising:
(a) a first composition comprising a CD4+ T cell comprising a chimeric engulfment receptor (CER) comprising:
an extracellular domain comprising a Tim4 extracellular domain that binds to phosphatidylserine,
an engulfment signaling domain, wherein the engulfment signaling domain comprises a TLR signaling domain, a TRAF2 signaling domain, a TRAF6 signaling domain, a DAP12 signaling domain, a NFAM1 signaling domain, a Baff-R signaling domain, or a CD79b signaling domain, and
a transmembrane domain positioned between and connecting the extracellular domain and the engulfment signaling domain; and
(b) a second composition comprising a CD8+ T cell comprising:
(i) a chimeric antigen receptor (CAR) comprising:
an extracellular domain comprising an antibody binding domain that binds to a target antigen,
an intracellular signaling domain, and
a transmembrane domain positioned between and connecting the extracellular domain and the intracellular signaling domain; or
(ii) a recombinant T cell receptor (TCR) that binds to a target antigen.